Vnitr Lek 2008, 54(1):101-118

Doporučení diagnostických a léčebných postupů u arteriální hypertenze - verze 2007. Doporučení České společnosti pro hypertenzi

J. Widimský jr1,*, R. Cífková2, J. ©pinar3, J. Filipovský4, M. Grundmann5, K. Horký6, A. Linhart6, V. Monhart7, H. Rosolová4, M. Souček8, J. Vítovec9, J. Widimský sr10
1 Centrum pro hypertenzi, III. interní klinika 1. lékařské fakulty UK a VFN Praha, přednosta prof. MUDr. ©těpán Svačina, DrSc., MBA
2 Pracoviątě preventivní kardiologie IKEM Praha, vedoucí doc. MUDr. Renata Cífková, CSc.
3 Interní kardiologická klinika Lékařské fakulty MU a FN Brno, pracoviątě Bohunice, přednosta prof. MUDr. Jindřich ©pinar, CSc., FESC
4 II. interní klinika Lékařské fakulty UK a FN Plzeň, přednosta doc. MUDr. Jan Filipovský, CSc.
5 Ústav klinické farmakologie FN Ostrava, přednosta doc. MUDr. Milan Grundmann, CSc.
6 II. interní klinika kardiologie a angiologie 1. lékařské fakulty UK a VFN Praha, přednosta prof. MUDr. Aleą Linhart, DrSc.
7 Interní klinika 1. lékařské fakulty a Ústřední vojenské nemocnice Praha, přednosta doc. MUDr. Miroslav Zavoral, Ph.D.
8 II. interní klinika Lékařské fakulty MU a FN u sv. Anny Brno, přednosta doc. MUDr. Miroslav Souček, CSc.
9 I. interní kardioangiologická klinika Lékařské fakulty MU a FN u sv. Anny Brno, přednosta prof. MUDr. Jiří Vítovec, CSc., FESC
10 Klinika kardiologie IKEM Praha, přednosta prof. MUDr. Jan Kautzner, CSc., FESC

Received: November 26, 2007; Published: January 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Widimský J, Cífková R, ©pinar J, Filipovský J, Grundmann M, Horký K, et al.. Doporučení diagnostických a léčebných postupů u arteriální hypertenze - verze 2007. Doporučení České společnosti pro hypertenzi. Vnitr Lek. 2008;54(1):101-118.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. Guidelines Committee. J Hypertens 2003; 21: 1011-1053.
    2. Cífková R, Horký K, Widimský J sr et al. Doporučení diagnostických a léčebných postupů u arteriální hypertenze - verze 2004. Doporučení české společnosti pro hypertenzi. Vnitř Lék 2004; 50: 709-722. Go to PubMed...
    3. Julius S, Kjeldsen SE, Weber M et al. VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-2031. Go to original source... Go to PubMed...
    4. Dahlof B, Sever PS, Poulter NR et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendoflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895-906. Go to original source... Go to PubMed...
    5. Patel A ADVANCE Collaborative Group et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 804-805. Go to original source... Go to PubMed...
    6. 2007 Guidelines for the Management of Arterial Hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension and of the European Society of Cardiology. Guidelines Committee. J Hypertens 2007; 25: 1105-1187.
    7. 2007 ESH-ESC Practice Guidelines for the management of Arterial hypertension. ESH-ESC Task Force on the management of Arterial Hypertension. J Hypertension 2007; 25: 1751-1762.
    8. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical practise. Guidelines Committee. Eur Heart J 2007; 28: 2375-2414.
    9. Staessen JA, Gasowski J, Wang JG et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000; 355: 865-872. Go to original source... Go to PubMed...
    10. Bulpitt CJ, Beckett NS, Cooke J et al. Hypertension in the Very Elderly Trial Working Group. Results of the pilot study for the Hypertension in the Very Elderly Trial. J Hypertens 2003; 21: 2409-2417. Go to original source... Go to PubMed...
    11. Widimský J et al. Hypertenze. 3. ed (přepracované) 2008, 1-520. Praha. Triton 2008.
    12. Mancia G, Brown M, Castaigne A Outcomes with nifedipine GITS or Coamilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). Hypertension 2003; 41: 431-436. Go to original source... Go to PubMed...
    13. Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens 2006; 24: 3-10. Go to original source... Go to PubMed...
    14. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997. Go to original source... Go to PubMed...
    15. Kannel WB, Wolf PA, Benjamin EJ et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998; 82: 2N-9N. Go to original source... Go to PubMed...
    16. Healey JS, Baranchuk A, Crystal E et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005; 45: 1832-1839. Go to original source...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.